Life with TGCT
Emactuzumab
About
Media

Expanded Access

Home
Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events
Publications
Press Releases
Expanded Access
Privacy Policy
Terms & Conditions

Home
Media
Publications
TANGENT study design

TANGENT study design

20 July 2026

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors

Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events

Publications
Press Releases
Expanded Access
Terms and Conditions
Privacy Policy

SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, an investigational, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

© Copyright 2026 SynOx Therapeutics. All rights reserved.

You are about to leave our website

We are not responsible for the content. Do you want to proceed?